Parameters for successful monthly extended dosing of Darbepoetin-α in patients undergoing hemodialysis

Clinical Nephrology

Volumn 71, Issue 6, 2009, Pages 697-702

  Trachsler, Johannes ^a   Gluck Z ^b   Dickenmann, M ^c   Gauthier, T ^d   Brunisholz M ^e   Martin, P Y ^f   Burnier, M ^g   Wahl, C ^h   Wuthrich R P ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Spitalzentrum Biel   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Hopital Riviera   (Switzerland)

^e Site de Porrentruy   (Switzerland)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h Departament de Nephrologie   (Switzerland)

Author keywords

Anemia; Darbepoetin ; Dialysis patients; Extended dosing

Indexed keywords

FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; SATISFACTION; ALGORITHM; ANEMIA; BLOOD; CHRONIC KIDNEY FAILURE; DRUG ADMINISTRATION; DRUG MONITORING; FEASIBILITY STUDY; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; STATISTICS; TREATMENT OUTCOME;

AGED; ALGORITHMS; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; ERYTHROPOIETIN; FEASIBILITY STUDIES; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 67651012542     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp71697     Document Type: Article

References (15)

1. Aranesp® Switzerland. Arzneimittel-Kompendium der Schweiz (Swiss Drug Compendium). Basel: Documed AG; 2008.
2. Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C. An open-label study of darbepoetin alfa administered once monthly for the maintenance of hemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. Journal of internal medicine. 2006; 260: 577-585.
3. Ardevol M, Fontseré N, Casals M, et al. A feasibility cost-analysis study of recombinant human erythropoietin and darbepoetin alfa in ambulatory hemodialysis patients during current clinical practice. Eur J Hospital Pharm Sci. 2006; 12: 47-51.
4. Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Nephrol Dial Transplant. 2007; 22 (Suppl): 19-30.
5. Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on hemodialysis. Nephrol Dial Transplant. 2006; 21: 2846-2850.
6. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006; 1: 1205-1210.
7. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003; 31: 290-299.
8. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J AmSoc Nephrol. 2007; 2: 1274-1282.
9. Globe D, Glidden D, Hertel J et al. Assessment if the impact of weekly versus monthly erythropoiesis stimulating protein therapy on patients with CKD and their families. Nephrol Nurs J. 2007; 34: 151-161
10. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ. Darbepoetin alfa administered once monthly maintains hemoglobin levels in stable dialysis patients. Nephrol Dial Transplant. 2004; 19: 898-903.
11. Kruep EJ, Basskin LE. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. Am J Health Syst Pharm. 2005; 62: 2597-2603.
12. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19 (Suppl): 1-47.
13. Mann J, Fraass U. Reduced frequency of administration of darbepoetin alfa (Aranesp®) in dialysis patients with renal anaemia. Nephrol Dial Transplant. 2003; 18: 166.
14. Summers S, Winnett G, Matijevic A, Carmichael D, Almond M. An audit comparing subcutaneous epoetin alfa to intravenous darbepoetin alfa in chronic hemodialysis patients. DialTransplant. 2005; 34: 358-362.
15. Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002; 62: 2167-2175.